Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.54 |
| ▸ | MAOA | P21397 | 7/20 | 0.48 |
| ▸ | MAOB | P27338 | 7/20 | 0.48 |
| ▸ | KDM1A | O60341 | 5/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15922990 | 1.00 | HSD11B1 (0.54) | HSD11B1MAOAMAOBKDM1ACHRM2 | |
| SCHEMBL17356681 | 0.85 | HSD11B1 (0.58) | HSD11B1MAOAMAOBCHRM2CHRM4 | |
| SCHEMBL6686528 | 0.75 | HSD11B1 (0.60) | HSD11B1MAOAMAOBKDM1ACHRM2 | |
| Hydrochloric Acid SCHEMBL6682912 | 0.74 | HSD11B1 (0.59) | HSD11B1MAOAMAOBKDM1ACHRM2 | |
| SCHEMBL3023692 | 0.73 | HSD11B1 (0.62) | HSD11B1 | |
| SCHEMBL5802127 | 0.71 | MAOA (0.50) | MAOAMAOBKDM1ARCOR1 | |
| SCHEMBL17356683 | 0.70 | HSD11B1 (0.48) | HSD11B1MAOAMAOBKDM1ACHRM2 | |
| SCHEMBL13216325 | 0.70 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL354182 | 0.69 | MEN1 (0.56) | HSD11B1MAOAMAOBKDM1A | |
| SCHEMBL15922387 | 0.69 | HSD11B1 (0.49) | HSD11B1MAOAMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840465-B2 | Antiviral compounds | UNIV BRIGHAM YOUNG (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840465-B2 | Antiviral compounds | UNIV BRIGHAM YOUNG (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150368196-A1 | ANTIVIRAL COMPOUNDS | UNIV BRIGHAM YOUNG (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368196-A1 | ANTIVIRAL COMPOUNDS | UNIV BRIGHAM YOUNG (US) | 2015-12-24 | — | — | US | disclosed |
| EP-2950789-A2 | ANTIVIRAL COMPOUNDS | Brigham Young University (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014121170-A2 | ANTIVIRAL COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014121170-A2 | ANTIVIRAL COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368196-A1 | ANTIVIRAL COMPOUNDS | ACE, ADA, MAVS | HSD11B1 1386/4885MAOA 74/4885MAOB 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.